相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
Maximilian Merz et al.
LEUKEMIA (2020)
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
Chenxing Du et al.
LEUKEMIA & LYMPHOMA (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Nadine Abdallah et al.
BLOOD ADVANCES (2020)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
Xiaozhe Li et al.
ONCOLOGIST (2019)
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2019)
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
R. Chakraborty et al.
LEUKEMIA (2018)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
Maximilian Merz et al.
BLOOD ADVANCES (2018)
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
Gunjan L. Shah et al.
LEUKEMIA & LYMPHOMA (2017)
Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma
Thomas Smol et al.
MOLECULAR CYTOGENETICS (2017)
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Herve Avet-Loiseau et al.
BLOOD (2017)
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Hareth Nahi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Fabian Bock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
Yuan Jian et al.
MEDICINE (2016)
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment
Gang An et al.
EXPERIMENTAL HEMATOLOGY (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens
Noa Biran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
Kai Neben et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben et al.
BLOOD (2012)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
分享论文
